secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001437749-23-017917
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on DiaMedica's DM199 acute ischemic stroke trial
------------------------------------------------------------------------

- FDA removed clinical hold on IND for DM199 phase 2/3 ReMEDy2 trial in acute ischemic stroke.
- Hold removal allows DiaMedica to proceed with enrollment and dosing in the trial.
- Investor presentation summarizing the update made available on June 21, 2023.
- No financial guidance or trial timeline details disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923017917/0001437749-23-017917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923017917/dmtp20230620c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-017917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer